AP20187, also known as AP-20187, is a chemical compound that has been developed for its potential therapeutic applications. It belongs to the class of dimerizer compounds, which are used in a wide range of biological applications. In this article, we will provide an overview of AP20187, including its chemical name, molecular formula, formula weight, CAS No., top ten keywords, synonyms, health benefits, potential effects, product mechanism, safety, side effects, and dosing information.
Chemical Name: The chemical name of AP20187 is 7-(4-(2,4-dioxo-3,4-dihydrothieno[2,3-d]pyrimidin-1(2H)-yl)phenyl)-6-methyl-3-tetrahydrofuranol.
Molecular Formula: The molecular formula of AP20187 is C25H26N2O5S.
Formula Weight: The formula weight of AP20187 is 474.55 g/mol.
CAS No: The CAS number of AP20187 is 195514-80-8.
Top Ten Keywords: The top ten keywords associated with AP20187 CAS: 195514-80-8 are:
Synonyms: The synonyms for AP20187 include:
Health Benefits: AP20187 has potential health benefits due to its ability to induce gene expression and regulate protein-protein interactions. It has been used in a variety of experimental settings to control the expression of genes of interest and to study signaling pathways involved in disease processes.
Potential Effects: The potential effects of AP20187 include:
Product Mechanism: AP20187 works by binding to a specific ligand-binding domain on a protein of interest, causing it to dimerize with another protein containing a complementary domain. This dimerization event then triggers downstream signaling events, leading to changes in gene expression or protein function.
Safety: The safety of AP20187 has not been extensively studied, but it is thought to be generally safe when used as directed. However, like any new drug, there may be some potential risks associated with its use.
Side Effects: The side effects of AP20187 are not well known, but some possible side effects may include nausea, vomiting, diarrhea, and fatigue.
Dosing Information: The optimal dose of AP20187 has not been established yet, and further studies are needed to determine the appropriate dosage for different conditions.
Conclusion: AP20187 represents a promising new compound with potential therapeutic applications in the fields of gene expression regulation and signal transduction. It works by inducing protein-protein interactions, leading to downstream effects on gene expression and protein function. While the safety and side effects of AP20187 are not well understood, further research is needed to establish its optimal dosage and ensure its safety in clinical trials. Overall, AP20187 presents an exciting avenue for the development of innovative therapies for a variety of diseases, including cancer and genetic disorders.